GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals

More

  • Actavis hard switch   Friday, 22 May 2015 | 2:30 PM ET
    Actavis hard switch

    A federal appeals court has made a ruling on a top selling Alzheimer's drug that could make things difficult for drugmaker Actavis, reports CNBC's Meg Tirrell.

  • This is the next big thing according to Mark Cuban Wednesday, 20 May 2015 | 5:12 PM ET
    Marc Cuban

    Mark Cuban said innovative tech in the pharmaceutical sector is going to be a game changer not only for health care, but for humanity.

  • J&J can weather new biotech threat: Analyst Wednesday, 20 May 2015 | 4:33 PM ET
    Johnson & Johnson

    Cheaper biotech drugs are headed to the U.S., but analyst Mike Weinstein thinks J&J can manage through some of the challenges.

  • How biotechs are affecting J&J's business   Wednesday, 20 May 2015 | 1:55 PM ET
    How biotechs are affecting J&J's business

    Michael Weinstein, JPM, managing director of healthcare, joins CNBC's Meg Tirrell to discuss biosimilar, the threat to big pharmaceuticals, and how Johnson & Johnson will be affected.

  • Scientists experiment to make old brains new again Wednesday, 20 May 2015 | 11:34 AM ET
    Mice in science lab

    Researchers at UC Irvine restored a key feature of young brains, the flexibility that allows for learning and creativity.

  • J&J: 10 new drugs by 2019, each with $1B potential Wednesday, 20 May 2015 | 9:11 AM ET
    Johnson & Johnson's Janssen Labs in La Jolla, California.

    "You're going to have some wins and some that don't turn out," J&J chief Alex Gorsky tells CNBC. "But overall we're very confident."

  • Pharmacy in meningitis outbreak to pay out $200M Tuesday, 19 May 2015 | 4:48 PM ET
    FDA-OCI agents entered New England Compounding Center (NECC) at 697 Waverly Street in Framingham, Mass.

    The New England Compounding Center sickened about 750 people and killed at least 64 across the United States three years ago.

  • Gene therapy's promise and hope for the blind: ONCE CEO

    Jeffrey Marrazzo, Spark Therapeutics CEO, and Dr. Jean Bennett, Spark Therapeutics advisor, discuss how advances in gene therapy are changing the way rare diseases are treated. And Gordon Gund, Gund Investment Corp. CEO, weighs in.

  • Endo to buy Par Pharmaceuticals for $8.05B Monday, 18 May 2015 | 8:42 AM ET
    pharmaceuticals pills

    "This will position us as a top-five generics player in the U.S.," Endo International CEO Rajiv De Silva says.

  • FDA warns on newer class of diabetes drugs Friday, 15 May 2015 | 11:53 AM ET
    Drug capsules and glass of water

    The agency warned that certain type 2 diabetes drugs may cause high levels of blood acid that could require hospitalization.

  • Cancer data deluge   Thursday, 14 May 2015 | 2:32 PM ET
    Cancer data deluge

    CNBC's Meg Tirrell breaks down all the biotech data coming out ahead of the ASCO Conference, and why Clovis Oncology's stock is climbing.

  • Viagra may help cure malaria Thursday, 14 May 2015 | 11:31 AM ET
    Viagra pill

    A new study suggests Viagra can fight malaria, which still infects millions and kills half a million people every year.

  • Bill Nye Kickstarts solar-powered space travel Thursday, 14 May 2015 | 10:49 AM ET
    A depiction of LightSail with its unfurled solar sails

    U.S. scientist Bill Nye, popularly known as "the Science Guy", has launched a Kickstarter to fund an satellite propelled by solar energy.

  • ASCO's immunotherapies update   Thursday, 14 May 2015 | 6:19 AM ET
    ASCO's immunotherapies update

    CNBC's Meg Tirrell takes a look at new cancer-fighting drugs and other therapies in the pipeline.

  • Biotech to watch ahead of ASCO   Wednesday, 13 May 2015 | 2:36 PM ET
    Biotech to watch ahead of ASCO

    The American Society of Clinical Oncology conference will occur at the end of May in Chicago. CNBC's Meg Tirrell reports which companies investors should watch. Also, Les Funtleyder, ESquared Asset Management, shares his view.

  • Hungover? Pedialyte wants your business Wednesday, 13 May 2015 | 2:51 PM ET
    Pedialyte a hangover cure? The company increases its focus on adult consumers.

    Pedialyte is going after a new market, and they don't have a bedtime...

  • Biotech investors: These are the key names to know Wednesday, 13 May 2015 | 11:53 AM ET
    Biotech

    Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.

  • 500,000 Americans spend $50K on medicine each year Wednesday, 13 May 2015 | 12:01 AM ET
    Prescription drugs

    More than half a million Americans have annual prescription drug costs of more than $50,000.

  • FDA panel approves Vertex drug   Tuesday, 12 May 2015 | 5:44 PM ET
    FDA panel approves Vertex drug

    A panel of outside advisers of the FDA recommended approval for Vertex Pharma's cystic fibrosis drug, reports CNBC's Meg Tirrell.

  • 'Disruptor' Moderna: Human drug trials coming soon Tuesday, 12 May 2015 | 2:27 PM ET
    An image of Stéphane Bancel of Moderna Therapeutics from a company video.

    If successful, Moderna Therapeutics' cutting-edge drug method could be used to fight cancer and some infectious diseases.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.